The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...
aDepartment of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg 69120, Germany bDepartment of Rheumatology, University Hospital Düsseldorf, ...
Almost 90% of a cohort of patients with systemic lupus erythematosus reported experiencing depression or depressive symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results